Recent study showed that GLX351322, a NADPH oxidase 4 (NOX4)-derived ROS inhibitor, has an inhibitory effect on thyroid carcinoma cell growth and disrupts the resistance of cancer cells to etoposide [62]. The gene discussed is NOX4; the disease is cancer.